Bayer: Have we maximised patient outcomes, or can we go further?
Location: Forum
Date & Time: Friday, 6 October, 09:45 - 10:45 CEST
Chairperson(s): Charles Wykoff USA
Speakers:
Presentations:
C. Wykoff USA
09:45 Introduction
G. Cheung SINGAPORE
09:50 Have we maximised outcomes for our patients?
M. Munk SWITZERLAND
10:00 Does the VEGFR pathway remain the master regulator in retinal disease?
P. Kaiser USA
10:10 Could aflibercept 8mg be a turning point in retinal care?
All Faculty
10:25 Expert Exchange
C. Wykoff USA
10:40 Summary
